Latest Breaking News On - Simon goldsborough - Page 2 : comparemela.com

Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics.

F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®

FDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the.

F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line

F. Hoffmann-La Roche Ltd: Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity